RPL17 and neoplasm: For example, studies show that ZDHHC3/9 modulates the tumor immune microenvironment by inhibiting PD- 1/L1 ubiquitination [21, 138], while our lab has found that ZDHHC20 stabilizes FASN by preventing its ubiquitin–proteasome mediated degradation, promoting liver cancer progression [110].